Advanced search
Publication Cover
Pharmacogenomics Volume 7, 2006 - Issue 5
Submit an article Journal homepage
535
Views
0
CrossRef citations to date
0
Altmetric
Review

Epigenetics: an Emerging Technology in the Diagnosis and Treatment of Cancer

Justin Stebbing1 St Bartholomew‘s Hospital, Department of Medical Oncology, London, UKView further author information
,
Mark Bower2 Chelsea and Westminster Hospital, Department of Medical Oncology, LondonSW10, UKView further author information
,
Nelofer Syed3 Institute for Cancer Research, Cancer Genetics and Epigenetics Laboratory, The Toby Robins Breakthrough Breast Cancer Centre, LondonSW3 6JB, UK. Tel: +44 207 153 5317; Fax: +44 207 153 5340;[email protected]View further author information
,
Paul Smith3 Institute for Cancer Research, Cancer Genetics and Epigenetics Laboratory, The Toby Robins Breakthrough Breast Cancer Centre, LondonSW3 6JB, UK. Tel: +44 207 153 5317; Fax: +44 207 153 5340;[email protected]View further author information
,
Veronica Yu4 Eukaryotic Chromatin Dynamics Group, MRC Clinical Sciences Centre, Imperial College, Hammersnith Campus, Du Cane Road, London, W12 ONN, UKView further author information
&
Tim Crook3 Institute for Cancer Research, Cancer Genetics and Epigenetics Laboratory, The Toby Robins Breakthrough Breast Cancer Centre, LondonSW3 6JB, UK. Tel: +44 207 153 5317; Fax: +44 207 153 5340;[email protected];5 Charing Cross Hospital, Department of Medical Oncology, Fulham Palace Road, LondonW6 8RF, UKView further author information
Pages 747-757 | Published online: 03 Aug 2006

Bibliography

  • Bhattacharya NP , SkandalisA, GaneshA, GrodenJ, MeuthM: Mutator phenotype in human colorectal carcinoma cell lines.Proc. Natl Acad. Sci. USA91, 6319–6323 (1994).
  • Yamashita K , UpadhyayS, OsadaM et al.: Pharmacological unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell2, 485–495 (2002).
  • Ushijima T , MorimuraK, HosoyaY et al.: Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc. Natl Acad. Sci. USA94, 2284–2289 (1997).
  • Rush LJ , PlassC: Restriction landmark genomic scanning for DNA methylation in cancer: past, present and future applications.Anal. Biochem.307, 191–201 (2002).
  • Ballestar E , PazMF, ValleL et al.: Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J22, 6335–6345 (2003).
  • Weber M , DaviesJJ, WittigD et al.: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genet.37, 853–862 (2005).
  • Wilson IM , DaviesJJ, WeberM et al.: Epigenomics. Mapping the methylome. Cell Cycle5, 155–158 (2006).
  • Herman JG , GraffJR, MyohanenS, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA93, 9821–9826 (1996).
  • Roman-Gomez J , Jimenez-VelascoA, Agirre X, Prosper F, Heiniger A, Torres A: Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J. Clin. Onc.23, 7043–7049 (2005).
  • Bergamaschi D , GascoM, HillerL et al.: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell3, 387–402 (2003).
  • Teodoridis JM , StrathdeeG, BrownR: Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.Drug Resist. Update7, 267–278 (2004).
  • Gifford G , PaulJ, VaseyPA, KayeSB, BrownR: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients.Clin. Cancer Res.10, 4420–4426 (2004).
  • Scolnick DM , HalazonetisTD: Chfr defines a mitotic stress checkpoint that delays entry into metaphase.Nature406, 430–445 (2000).
  • Burns TF , FeiP, ScataKA, DickerDT, El-DeiryWS: Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol®)-exposed cells.Mol. Cell Biol.23, 5556–5571 (2003).
  • Syed N , SmithP, SullivanA et al.: Transcriptional silencing of Polo-like kinase 2 (Snk/Plk2) is a frequent event in B-cell malignancies. Blood107, 250–256 (2006).
  • Taniguchi T , TischkowitzM, AmezianeN et al.: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Med.9, 568–574 (2003).
  • Feinberg AP , GehrkeCW, KuoKC, Ehrlich M: Reduced genomic 5-methylcytosine in human colonic neoplasia. Cancer Res.48, 1159–1161 (1988).
  • Roman-Gomez J , Jimenez-VelascoA, Agirre X et al.: Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene24, 7213–7223 (2005).
  • Gore SD : Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.Nature Clin. Pract. Oncol.2(Suppl. 1), S30–S35 (2005).
  • Baylin SB : DNA methylation and gene silencing in cancer.Nature Clin. Pract. Oncol.2(Suppl. 1), S4–S11 (2005).
  • Fenaux P : Inhibitors of DNA methylation: beyond myelodysplastic syndromes.Nature Clin. Pract. Oncol.2(Suppl. 1), S36–S44 (2005).
  • Novik KL , NimmrichI, GencB et al.: Epigenomics: genome-wide study of methylation phenomena. Curr. Issues Mol. Biol.4, 111–128 (2002).
  • Economopoulos T , StathakisN, FoudoulakisA et al.: Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification. Eur. J. Haematol.38, 338–344 (1987).
  • Kerkhofs H , HermansJ, HaakHL, Leeksma CH: Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br. J. Haematol.65, 73–81 (1987).
  • Silverman LR , DemakosEP, PetersonBL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol.20, 2429–2440 (2002).
  • Kantarjian HM : Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.J. Clin. Oncol.20, 2415–2416 (2002).
  • Christman JK , MendelsohnN, HerzogD, SchneidermanN: Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60).Cancer Res.43, 763–769 (1983).
  • Razin A , RiggsAD: DNA methylation and gene function.Science210, 604–610 (1980).
  • Aggerholm A , HolmMS, GuldbergP, OlesenLH, HoklandP: Promoter hypermethylation of p15, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.Eur. J. Haematol.76, 23–32 (2006).
  • Hackanson B , GuoY, LubbertM: The silence of the genes: epigenetic disturbances in hematopoietic malignancies.Expert Opin. Ther. Targets9, 45–61 (2005).
  • Guo Y , EngelhardtM, WiderD, AbdelkarimM, LubbertM: Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells.Leukemia20, 115–121 (2005).
  • de Vos D : Epigenetic drugs: a longstanding story.Semin. Oncol.32, 437–442 (2005).
  • Wijermans PW , LubbertM, VerhoefG, KlimekV, BoslyA: An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.Ann. Hematol.84(Suppl. 13), 9–17 (2005).
  • Balch C , YanP, CraftT et al.: Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther.4, 1505–1514 (2005).
  • Field JK , LiloglouT, WarrakS et al.: Methylation discriminators in NSCLC identified by a microarray based approach. Int. J. Oncol.27, 105–111 (2005).
  • Scholz C , NimmrichI, BurgerM et al.: Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Ann. Hematol.84, 236–244 (2005).
  • Guo J , BurgerM, NimmrichI et al.: Differential DNA methylation of gene promoters in small B-cell lymphomas. Am. J. Clin. Pathol.124, 430–439 (2005).
  • Toyota M , KopeckyKJ, ToyotaMO, Jair KW, Willman CL, Issa JP: Methylation profiling in acute myeloid leukemia. Blood97, 2823–2829 (2001).
  • Harbeck N , BohlmannI, RossJS, MaierS: Mutlicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated node negative breast cancer using paraffin-embedded tumor tissue. ASCO. Orlando, USA (2005).
  • Ferguson AT , EvronE, UmbrichtCB et al.: High frequency of hypermethylation of 14–3-3σ locus leads to gene silencing in breast cancer. Proc. Natl Acad. Sci. USA97, 6049–6054 (2000).
  • Gasco M , BellAK, HeathV et al.: Epigenetic inactivation of 14–3-3σ in oral carcinoma: association with p16 (INK4a) silencing and human papillomavirus negativity. Cancer Res.62, 2072–2076 (2002).
  • Agirre X , Roman-GomezJ, Jimenez-VelascoA et al.: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene25, 1862–1870 (2006).
  • Corn PG , KuerbitzSJ, van Noesel MM et al.: Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Res59, 3352–3356 (1999).
  • Teodoridis JM , HallJ, MarshS et al.: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res65, 8961–8967 (2005).
  • Soengas MS , CapodieciP, PolskyD et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature409, 207–211 (2001).
  • Esteller M , Garcia-FoncillasJ, AndionE et al.: Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343, 1350–1354 (2000).
  • Esteller M , GaidanoG, GoodmanSN et al.: Hypermethylation of the DNA repair gene O (6)-methylguanine DNA transferase and survival of patients with diffuse large B-cell lymphoma. J. Natl Cancer Inst.94, 6–7 (2002).
  • Chang HG , KimSJ, ChungKW et al.: Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor β but not the estrogen receptor α gene. J. Mol. Med.83, 132–139 (2005).
  • Domann FE , RiceJC, HendrixMJ, FutscherBW: Epigenetic silencing of maspin gene expression in human breast cancers.Int. J. Cancer85, 805–810 (2000).
  • Graff JR , GabrielsonE, FujiiH, BaylinSB, HermanJG: Methylation patterns of the E-cadherin 5‘ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression.J. Biol. Chem.275, 2727–2732 (2000).
  • Graff JR , GreenbergVE, HermanJG et al.: Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle‘s cell, and poorly differentiated human thyroid carcinoma. Cancer Res.58, 2063–2066 (1998).
  • Sato N , FukushimaN, ChangR, MatsubayashiH, GogginsM: Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.Gastroenterology130, 548–565 (2006).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.